Leveraging deep expertise

About Us

Hinge Bio, Inc. is a privately-held biotechnology company leveraging its powerful GEM-⁠DIMER™ platform to develop therapeutics that address the problems of resistance, inadequate efficacy, and side effects in the fields of autoimmunity, cancer, inflammatory disease and infectious disease.

The GEM-DIMER™ technology uniquely enables (i) cooperative binding to disease targets allowing for orders-of-magnitude enhanced activity and (ii) greater degrees of multivalency and multispecificity than possible with conventional approaches, to produce molecules with entirely new functionality for superior safety and efficacy.

Management Team

Harold E. “Barry” Selick, Ph.D.

Chief Executive Officer & Director

Carin Rollins

Carin Mueller Rollins, MBA

Co-Founder & Chief Operating Officer

Daniel Capon

Daniel Capon, Ph.D.

Co-Founder & Chief Scientific Officer

Juha Punnonen, M.D., Ph.D.

Chief Development Officer

Joshua Carle, MBA

Chief Business Officer

Miriam Siekevitz

Miriam Siekevitz, Ph.D., J.D.

Co-Founder, General Counsel & Chief Administrative Officer

Robert Hershberg

Robert Hershberg, Ph.D.

Vice President, Manufacturing

Board of Directors

Misha Petkevich

J. Misha Petkevich, D.Phil.

Director & Chairman

Malcolm Gefter

Malcolm L. Gefter, Ph.D.

Director

Harold E. “Barry” Selick, Ph.D.

Chief Executive Officer & Director

Jeffrey Long-McGie

Board Observer

Alex Silverstein

Director

Scientific Advisory Board

Samuel Broder

Samuel Broder, M.D.

Chair, Scientific Advisory Board

The Scientific Advisory Board is comprised of scientists and clinicians who have made major contributions to the development of therapies and treatment of patients living with autoimmune disease as well as cancer and inflammatory disease.